PVP Ventures has established July 20, 2026 as the record date to determine eligibility for interest payments on its Non-Convertible Debentures (NCDs). The company will disburse the interest to qualified debenture holders on the following day, July 21, 2026. This schedule ensures that only investors listed in the Register of Debenture Holders or the list of beneficial owners as of the record date receive the due payments.

The intimation was submitted to the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 60(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure specifies the details of the NCD tranches involved in this interest payment cycle.

NCD Details

The record date and payment schedule apply to two specific NCD series. The table below outlines the specific ISINs and corresponding dates for the transaction.

Prasad V. Potluri, Chairman & Managing Director of PVP Ventures , signed the disclosure on July 14, 2026. The corporate office is located in Banjara Hills, Hyderabad, while the registered office is situated in Chennai.

PVP Ventures has increased its shareholding in 7 Med India Private Limited to 41.23% following the acquisition of an additional 4,263 equity shares. The transaction, completed on July 7, 2026, is part of the company's strategic expansion into the healthcare sector and represents the second tranche of a larger investment plan. The total outlay for the majority shareholding of 50.62% is expected to be around INR 127 crores.

The acquisition was executed in accordance with the Share Purchase Agreement and Shareholders' Agreement between the parties. 7 Med India Private Limited is among the top five organized players in India's renal care sector, offering a comprehensive range of dialysis services across its pan-India network. The company became an associate of PVP Ventures following the first tranche of acquisition on November 4, 2025.

The transaction does not fall within the ambit of a related party transaction and was undertaken on an arm's length basis. No governmental or regulatory approvals were required for this specific acquisition. The consideration for the transaction was paid in cash.

PVP Ventures remains committed to completing the balance acquisition to increase its aggregate stake to 50.62% in the target company. The timeline for the final tranche will be governed by the terms of the definitive agreements already executed between the parties.

Details of Acquisition